IkariaÃ‚® to Present at 31st Annual Cowen and Company Healthcare Conference
CLINTON, N.J., March 2, 2011 /PRNewswire/ -- Ikaria, Inc. today announced that its Chairman and CEO, Daniel Tasse, will present at the 31st Annual Cowen and Company Healthcare Conference on Wednesday, March 9, 2011 at 8:30 a.m. EST. The conference will be held March 7-9 at the Boston Marriott Copley Place in Boston.
About Ikaria, Inc.Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies for critically ill patients in the hospital and ICU settings. Ikaria's therapies are designed to meet the unique and complex medical needs of these critically ill patients. The company's lead product is the INOMAX® therapy package, an all-inclusive offering of drug product, training, services and drug-delivery technologies. INOMAX (nitric oxide) for inhalation, the drug included in the customer offering, is the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. The INOMAX therapy package also is available in Puerto Rico, Canada, Australia, Mexico and Japan. Ikaria acquired the North American and Australian rights to LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide license to IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The company also has a number of investigational compounds in development. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit www.ikaria.com. Company Contact:Media Contacts:Samina Bari
Tiberend Strategic Advisors, Inc.Ikaria, Inc.